ASH 2022 | Prevalence of MGCS among patients with monoclonal gammopathies

Efstathios Kastritis • 11 Dec 2022

ASH 2022

General

Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, outlines results from a database study analyzing the prevalence of monoclonal gammopathy of clinical significance (MGCS) in patients with monoclonal gammopathies. Overall, MGCS was found in ~4% of patients with monoclonal gammopathies in a plasma cell dyscrasia referral center. Among those with MGCS, the majority had either monoclonal gammopathy of renal significance (MGRS) or peripheral neuropathy. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

GSK: Honoraria; Takeda: Honoraria; Pfizer: Honoraria, Research Funding; Genesis Pharma: Honoraria; Janssen: Honoraria, Research Funding; Amgen: Honoraria, Research Funding.